Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Daylami, Rouzbeh ^a   Muilenburg, Diego J ^a   Virudachalam, Subbulakshmi ^a   Bold, Richard J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Gemcitabine; Pancreatic cancer; PEG ADI; RRM2

Indexed keywords

AMMONIA; ARGININE; ASPARTIC ACID; CASPASE 3; CITRULLINE; GEMCITABINE; LYSINE; PEGARGIMINASE; PHOSPHOSERINE; RIBONUCLEOTIDE REDUCTASE; TRANSCRIPTION FACTOR E2F1; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; E2F1 PROTEIN, HUMAN; HYDROLASE; MACROGOL DERIVATIVE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOTIDE REDUCTASE M2;

ADVANCED CANCER; ANIMAL EXPERIMENT; ARTICLE; CELL CYCLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; ENZYME SUBUNIT; FLOW CYTOMETRY; GROWTH DISORDER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METABOLIC STRESS; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ANIMAL; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; METABOLISM; NUDE MOUSE; PANCREATIC NEOPLASMS; PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; E2F1 TRANSCRIPTION FACTOR; HUMANS; HYDROLASES; MICE, NUDE; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; SIGNAL TRANSDUCTION; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84965191759     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0102-9     Document Type: Article

References (35)

1. Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997, 6:2403 2413.
2. Tang Y, Liu F, Zheng C, Sun S, Jiang Y: Knockdown of clusterin sensitizes pancreatic cancer cells to gemcitabine chemotherapy by ERK1/2 inactivation. J Exp Clin Cancer Res 2012, 31:73.
3. Awasthi N, Zhang C, Hinz S, Schwarz MA, Schwarz RE: Enhancing sorafenibmediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II. J Exp Clin Cancer Res 2013, 32:12.
4. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ: Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003, 113:88 95.
5. Mini E, Nobili S, Caciagli B, Landini I, Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17(Supplement 5):v7 v12.
6. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ: In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 2005, 65(20):9510 9516.
7. Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res 2004, 64(11):3761 3766.
8. van der Wilt CL, Kroep JR, Bergman AM, Loves WJ, Alvarez E, Talianidis I, Eriksson S, van Groeningen CJ, Pinedo HM, Peters GJ: The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 2000, 486:287 290.
9. Bergman AM, Pinedo HM, Peters GJ: Determinants of resistance to 2?, 2?-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 2002, 5:19 33.
10. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004, 23(8):1539 1548.
11. Rjiba S, Bigand C, Parmentier C, Hajri A: Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies. Neoplasia 2009, 11(7):637650.
12. Lin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, Cory JG, Sartorelli AC: Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochem Pharmacol 2007, 73:760? 772.
13. Chabes AL, Bjrklund S, Thelander L: S Phase-specific transcription of the mouse ribonucleotide reductase R2 gene requires both a proximal repressive E2F-binding site and an upstream promoter activating region. J Biol Chem 2004, 279(11):10796 10807.
14. Jung CP, Motwani MV, Schwartz GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001, 7(8):2527 2536.
15. Yoshimoto T, Boehm M, Olive M, Crook MF, San H, Langenickel T, Nabel EG: The arginine methyltransferase PRMT2 binds RB and regulates E2F function. Exp Cell Res 2006, 312(11):2040 2053.
16. Radisavljevic Z: Inactivated tumor suppressor Rb by nitric oxide promotes mitosis in human breast cancer cells. J Cell Biochem 2004, 92(1):1 5.
17. Bowles TL, Kim R, Galante J, Parsons CM, Virudachalam S, Kung HJ, Bold RJ: Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase. Int J Cancer 2008, 123(8):1950 1955.
18. Kelly MP, Jungbluth AA, Wu BW, Bomalaski J, Old LJ, Ritter G: Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase. Br J Cancer 2012, 106(2):324 332.
19. Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, Leung YC: Pegylated recombinant human arginase (rhArg-peg5,000 mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res 2007, 67(1):309 317.
20. Ensor CM, Holtsberg FW, Bomalaski JS, Clark MA: Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002, 62(19):5443 5450.
21. Ascierto PA, Scala S, Castello G, Daponte A, Simeone E, Ottaiano A, Beneduce G, DeRosa V, Izzo F, Melucci MT, Ensor CM, Prestayko AW, Holtsberg FW, Bomalaski JS, Clark MA, Savaraj N, Feun LG, Logan TF: Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. JClinOncol2005, 23(30):7660 7668.
22. Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW: Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep 2007, 18(6):1373? 1377.
23. Feun LG, Marini A, Walker G, Elgart G, Moffat F, Rodgers SE, Wu CJ, You M, Wanopaichitr M, Kuo MT, Sisson W, Jungbluth AA, Bomalaski J, Savaraj N: Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase. Br J Cancer 2012, 106(9):1481 1485.
24. Kim RH, Coates JM, Bowles TL, McNerney GP, Sutcliffe J, Jung JU, Gandour-Edwards R, Chuang TY, Bold RJ, Kung HJ: Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis. Cancer Res 2009, 69(2):700 708.
25. Revenko AS, Kalashnikova EV, Gemo AT, Zou JX, Chen HW: Chromatin loading of E2F-MLL complex by cancer-associated coregulator ANCCA via reading a specific histone mark. Mol Cell Biol 2010, 30(22):5260 5272.
26. Pan X, Arumugam T, Yamamoto T, Levin PA, Ramachandran V, Ji B, Lopez-Berestein G, Vivas-Meija PE, Sood AK, McConkey DJ, Logsdon CD: Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells. Clin Cancer Res 2008, 14(24):8143 8151.
27. Ohhashi S, Ohuchida K, Mizumoto K, Fujita H, Egami T, Yu J, Toma H, Sadatomi S, Nagai E, Tanaka M: Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer. Anticancer Res 2008, 28(4B):2205 2212.
28. Glazer ES, Piccirillo M, Albino V, Di Giacomo R, Palaia R, Mastro AA, Beneduce G, Castello G, De Rosa V, Petrillo A, Ascierto PA, Curley SA, Izzo F: Phase II study of pegylated arginine deiminase for nonresectable and metastatic hepatocellular carcinoma. J Clin Oncol 2010, 28(13):2220 2226.
29. Phillips MM, Sheaff MT, Szlosarek PW: Targeting arginine-dependent cancers with arginine-degrading enzymes: opportunities and challenges. Cancer Res Treat 2013, 45(4):251 262.
30. Savaraj N, You M, Wu C, Wangpaichitr M, Kuo MT, Feun LG: Arginine deprivation, autophagy, apoptosis (AAA) for the treatment of melanoma. Curr Mol Med 2010, 10(4):405 412.
31. Kim RH, Bold RJ, Kung HJ: ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer. Autophagy 2009, 5(4):567 568.
32. Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T, Szlosarek PW: Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 2010, 126(12):2762? 2772.
33. Tsai WB, Aiba I, Lee SY, Feun L, Savaraj N, Kuo MT: Resistance to arginine deiminase treatment in melanoma cells is associated with induced argininosuccinate synthetase expression involving c-Myc/HIF-1alpha/ Sp4. Mol Cancer Ther 2009, 8(12):3223? 3233.
34. Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, Park IS, Yoon DK, Min BH: Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer 2007, 120(4):897 905.
35. Gong H, Pttgen C, Stben G, Havers W, Stuschke M, Schweigerer L: Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 2003, 106(5):723 728.